Cholesterol doesn’t announce itself. It doesn’t cause pain, doesn’t slow you down, doesn’t give you so much as a headache while it builds up in your arteries over years. Most people find out they have a problem during a routine blood test, get handed a prescription for a daily pill, and are told they’ll be taking it for the rest of their life. Some do. Many don’t.
That last part is the real story. The gap between “prescribed” and “actually taken” has plagued heart disease prevention for decades. Statins work. PCSK9 inhibitor injections work better for many people. And yet the drugs sit in cabinets, the appointment to pick up the next round of shots gets missed, and LDL cholesterol (the “bad” kind that deposits plaque in artery walls) creeps back up. What medicine has never been able to solve is the simple human problem of asking people to do something every single day, or every few weeks, indefinitely.
Now a cholesterol treatment gene therapy called VERVE-102 is offering a genuinely different answer to that problem – not a better pill, not a longer-lasting injection, but a single infusion that could, potentially, reprogram how your liver handles cholesterol forever.
What Heart Disease Actually Costs
Heart disease is the leading cause of death in the United States, and in 2023 alone, 919,032 people died from cardiovascular disease – roughly one in every three deaths. The condition isn’t a rarity confined to people who made bad choices. It runs in families, it compounds over decades, and it kills people who thought they were doing everything right.
Elevated LDL cholesterol is one of the most direct drivers of that toll. The plaque it deposits in artery walls doesn’t just sit there – it narrows blood flow, hardens over time, and sets the stage for heart attacks and strokes.
Statins, the daily cholesterol-lowering pills most people are familiar with, have saved an enormous number of lives. A 2025 meta-analysis in ScienceDirect found that good statin adherence reduces the risk of all-cause mortality by 35%, and cuts the risk of heart attack by 30% compared to poor adherence. The problem is the word “adherence.” You only get those benefits if you keep taking the drug – and most people don’t, not forever.
Why Medications Keep Failing People
The same 2025 meta-analysis found that stopping statins altogether increases mortality risk by 90%. That pattern holds across different drugs in the same class. The injectable PCSK9 inhibitors, which lower LDL more powerfully than most statins and are given by injection every two weeks or monthly, face the same reality. Between 30% and 50% of people stop using them within a year.
Think about what that actually means in practice. Someone has a cardiac event – or their doctor spots dangerously high LDL at a checkup – and they’re prescribed a treatment that genuinely works. They use it for a while. Then life gets in the way. The injection needs refrigeration. The schedule slips. The cost is prohibitive without good insurance. Side effects are manageable but annoying enough to make skipping a dose feel reasonable. And before long, the cholesterol is climbing again.
PCSK9 is a protein made in the liver that regulates how much LDL cholesterol gets cleared from the blood. When PCSK9 is active, it blocks receptors on liver cells that would otherwise grab LDL from the bloodstream and remove it. Inhibiting PCSK9 removes that block, and LDL levels drop. Scientists figured out how to do this with injectable antibody drugs, and the results were significant – but the delivery method carried all the same compliance problems as every other long-term medication. In December 2025, the FDA approved a third-generation PCSK9 inhibitor called lerodalcibep (Lerochol) to reduce LDL cholesterol in adults – self-administered as a monthly subcutaneous injection, and notably storable at room temperature for up to three months. The science keeps getting better. The fundamental inconvenience of lifelong medication has remained.
The Gene Editing Approach
This is where VERVE-102 does something structurally different. Rather than introducing a drug that blocks PCSK9 over and over again, it uses a technique called base editing to go into the PCSK9 gene in liver cells and change it directly. Think of base editing as a precise molecular correction tool – it finds a single letter in the DNA sequence and rewrites it, like fixing a typo rather than deleting or replacing an entire sentence. The goal is to permanently switch off the gene’s ability to produce the PCSK9 protein in the first place.
VERVE-102 is an investigational base-editing therapy designed to durably inactivate PCSK9 in the liver, administered as a single intravenous infusion to adults with heterozygous familial hypercholesterolemia (an inherited condition that causes dangerously high LDL from birth) or premature coronary artery disease.
Eli Lilly and Company, which acquired Verve Therapeutics for $1 billion, announced positive Phase 1b results for VERVE-102 on May 25, 2026 – a single infusion designed to durably turn off the PCSK9 gene in the liver and lower LDL cholesterol. The results, published simultaneously in the New England Journal of Medicine and presented at the European Atherosclerosis Society Congress, marked the most detailed look yet at how well the therapy actually performs in people.
What the Trial Found
The interim analysis included 35 participants who each received a single intravenous infusion of VERVE-102 across six dose levels, ranging from 0.3 to 1.0 milligrams per kilogram of body weight. All participants received their full planned dose and were followed for at least 28 days, with a subset now followed for up to 18 months.
According to Eli Lilly’s announcement, PCSK9 levels dropped between 55% and 88% while LDL levels fell between 9% and 62%, depending on the dose received. The range is wide because the study was designed to test six different dose levels – the 62% LDL reduction came at the highest dose tested. To put that in context, most people taking a daily statin at maximum dose see LDL reductions of roughly 50%. Getting that kind of result from a single infusion, with effects that held for a year and a half, is what cardiologists are paying close attention to.
Investigators reported no treatment-related adverse events. The main side effects were infusion reactions and fatigue, and no one withdrew from the trial. That clean safety profile matters more than it might seem, because Verve’s earlier candidate – a predecessor to VERVE-102 – had to be shelved due to safety concerns. The fact that this version moved through a Phase 1 trial without triggering any serious adverse events is a meaningful step forward.
The reduction achieved was similar to that generated by Amgen’s marketed product Repatha, one of the approved injectable PCSK9 inhibitors, in people with genetic high cholesterol – though the two drugs haven’t been tested head to head.
Why the Durability Matters So Much
One of the most important questions with any gene therapy is whether the effect lasts. Liver cells don’t live forever – they turn over on a cycle of roughly 200 to 300 days. So how does editing today’s liver cells help the liver you’ll have in three years?
The answer lies in how cell division works. When an edited liver cell replicates, it passes the modified DNA to both daughter cells. Those new cells carry the same PCSK9 edit, and they pass it on in turn. VERVE-102 edits genes in liver cells so they continuously produce a changed version of PCSK9 that results in lower cholesterol. The alteration the therapy creates is not an exact copy of the naturally occurring low-cholesterol gene variant, but the end result is the same: the gene is inactivated and LDL levels drop.
Patients in the study have been followed for about 18 months and continue to show low LDL levels. Lilly has also reported that animal studies show sustained low LDL for at least three years, which gives the research team confidence that the treatment’s effect holds beyond the current human follow-up window.
That durability is the entire premise of the cholesterol treatment gene therapy approach. If the edit is maintained through cell turnover, then a single infusion at age 45 could theoretically keep your LDL in check at age 75 without you ever having to think about it again. That’s not a claim the researchers are making yet, but it’s the direction the evidence is pointing.
Where Things Stand Now
The FDA has previously fast-tracked the study of VERVE-102, and Eli Lilly has said it plans to launch a larger Phase 2 study by the end of 2026. Phase 2 will involve more participants, more dose groups, longer follow-up periods, and greater scrutiny of both safety and efficacy before the therapy could ever be considered for approval. Getting through Phase 1 without major safety flags is encouraging, but it’s still early days.
It’s also worth being clear about who the therapy is currently being tested in. The Heart-2 trial is evaluating VERVE-102 specifically in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease – two populations where LDL is elevated by genetics or early onset disease and where existing treatments haven’t been enough. This isn’t, at least not yet, a therapy for someone whose LDL is a little high because of diet and a sedentary job. It’s being tested in people for whom the standard options have already failed or proven unworkable long-term.
Keep that scope in mind. The research is genuinely exciting, but news cycles have a tendency to accelerate from “promising Phase 1 results in a specific high-risk population” to “cure for cholesterol” faster than the science warrants. What this trial shows is that base editing of the PCSK9 gene is biologically feasible in humans, that the LDL reductions are real and lasting for at least 18 months, and that the safety profile so far is clean. That’s a strong foundation – not a finish line, but a foundation.
In the meantime, managing cholesterol through lifestyle and medication remains the most reliable tool available to most people. The 2026 cholesterol guidelines, updated for the first time in eight years, now recommend that some high-risk patients consider starting statin therapy as early as age 30 – a shift that reflects how much earlier cardiovascular damage actually begins.
What to Do With All of This
The gap between a promising Phase 1 result and a therapy your doctor can actually prescribe is typically measured in years, sometimes a decade. Regulatory review, large-scale efficacy trials, safety monitoring across thousands of patients, cost negotiations with insurers – all of it takes time, and most promising therapies don’t survive the full journey. Drug development works that way by design, and for good reason.
But what makes VERVE-102 stand apart from the usual pipeline news is that it isn’t trying to make people better at taking their medication. It’s trying to make the medication a one-time event. That’s a structural shift in thinking about a disease that has historically assumed lifelong patient compliance – something that looks great in trial conditions and breaks down, predictably, in the rest of life.
If the Phase 2 data hold, and if the safety profile remains clean across a larger and more diverse population, this kind of cholesterol treatment gene therapy could eventually offer something medicine has never really had for cardiovascular prevention: a solution that doesn’t depend on whether you remember to take it. For now, the honest answer is that it’s early, the signal is strong, and the next few years of data will tell us a great deal about whether that promise holds.